AIMS: To review the results of hypofractionated radiotherapy in T1N0M0 squamous cell carcinoma of the larynx. MATERIALS AND METHODS: A series of 100 patients treated with radiotherapy between 1993 and 2001 was reviewed. The median age was 67 years. The median follow-up was 7 years (range 3-14 years). Radiotherapy was delivered to a total dose of 50 Gy in 16 fractions treating daily, 5 days a week over 21 days. RESULTS: Locoregional control rates with radiotherapy alone were 92% at 2 years and 88% at 5 years. After salvage surgery, the ultimate locoregional control rate was 96%. The relapse-free survival rates at 2 and 5 years were 85 and 70%, respectively. The cause-specific survival rates at 2 and 5 years were 99 and 97%, respectively. Overall survival rates at 2 and 5 years were 91 and 76%, respectively. Second primary cancers occurred in 21% of patients, primarily in the lung. CONCLUSIONS: Radiotherapy to a total dose of 50 Gy in 16 fractions for T1N0M0 squamous cell carcinoma of the larynx offers high locoregional control rates with voice preservation. These results from a hypofractionated radiotherapy schedule are comparable with other longer fractionation schedules and offer potential for optimising resource usage.
AIMS: To review the results of hypofractionated radiotherapy in T1N0M0 squamous cell carcinoma of the larynx. MATERIALS AND METHODS: A series of 100 patients treated with radiotherapy between 1993 and 2001 was reviewed. The median age was 67 years. The median follow-up was 7 years (range 3-14 years). Radiotherapy was delivered to a total dose of 50 Gy in 16 fractions treating daily, 5 days a week over 21 days. RESULTS: Locoregional control rates with radiotherapy alone were 92% at 2 years and 88% at 5 years. After salvage surgery, the ultimate locoregional control rate was 96%. The relapse-free survival rates at 2 and 5 years were 85 and 70%, respectively. The cause-specific survival rates at 2 and 5 years were 99 and 97%, respectively. Overall survival rates at 2 and 5 years were 91 and 76%, respectively. Second primary cancers occurred in 21% of patients, primarily in the lung. CONCLUSIONS: Radiotherapy to a total dose of 50 Gy in 16 fractions for T1N0M0 squamous cell carcinoma of the larynx offers high locoregional control rates with voice preservation. These results from a hypofractionated radiotherapy schedule are comparable with other longer fractionation schedules and offer potential for optimising resource usage.
Authors: David J Thomson; David Palma; Matthias Guckenberger; Panagiotis Balermpas; Jonathan J Beitler; Pierre Blanchard; David Brizel; Wilfred Budach; Jimmy Caudell; June Corry; Renzo Corvo; Mererid Evans; Adam S Garden; Jordi Giralt; Vincent Gregoire; Paul M Harari; Kevin Harrington; Ying J Hitchcock; Jorgen Johansen; Johannes Kaanders; Shlomo Koyfman; J A Langendijk; Quynh-Thu Le; Nancy Lee; Danielle Margalit; Michelle Mierzwa; Sandro Porceddu; Yoke Lim Soong; Ying Sun; Juliette Thariat; John Waldron; Sue S Yom Journal: Radiother Oncol Date: 2020-07-27 Impact factor: 6.280
Authors: David J Thomson; David Palma; Matthias Guckenberger; Panagiotis Balermpas; Jonathan J Beitler; Pierre Blanchard; David Brizel; Wilfred Budach; Jimmy Caudell; June Corry; Renzo Corvo; Mererid Evans; Adam S Garden; Jordi Giralt; Vincent Gregoire; Paul M Harari; Kevin Harrington; Ying J Hitchcock; Jorgen Johansen; Johannes Kaanders; Shlomo Koyfman; J A Langendijk; Quynh-Thu Le; Nancy Lee; Danielle Margalit; Michelle Mierzwa; Sandro Porceddu; Yoke Lim Soong; Ying Sun; Juliette Thariat; John Waldron; Sue S Yom Journal: Int J Radiat Oncol Biol Phys Date: 2020-04-14 Impact factor: 7.038